Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAardvark Therapeutics, Inc. Common Stock

Aardvark Therapeutics, Inc. Common Stock

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.31 USD 0.14 ( 11.97%)
Last update at 2026-11-09T15:24:00Z
VOLUME
113211
Market Cap
109.86M

Momentum Score

…

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.17
Low
1.32
High
52 Week Price Range
3.35
Low
17.94
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Aardvark Therapeutics (NASDAQ: AARD) appears to be a clinical-stage biotechnology company developing engineered regulatory T‑cell therapies for autoimmune and inflammatory conditions. Long-term growth drivers may include successful clinical trial progression, regulatory milestones, strategic collaborations and broader adoption of targeted cell therapies, which could support future commercial opportunities.

Material risks include early-stage clinical and regulatory uncertainty, probable future capital needs, manufacturing and scale-up challenges, and intense competition in the cell therapy space.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.17
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.00
ROE
-66.02%
Net Debt
-46.61M
ROCE
-54.01%
Diluted EPS TTM
-2.91

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Income before tax -57.59M -20.59M -7.21M -13.56M
Net income -57.59M -20.59M -7.21M -13.56M
Selling general administrative 13.79M 5.30M 2.17M 2.70M
Gross profit -0.04M -0.02M -0.10M -0.11M
Reconciled depreciation 0.04M 0.02M 0.10M 0.11M
Ebit -57.59M -22.67M -6.65M -10.87M
Ebitda -57.55M -22.65M -6.56M -10.76M
Depreciation and amortization 0.04M 0.02M 0.10M 0.11M
Operating income -62.73M -22.79M -7.42M -11.36M
Other operating expenses 62.73M 22.79M 7.42M 11.36M
Interest income 5.14M 2.41M 1.42M 0.12M
Net interest income 5.14M 2.41M 1.42M 0.12M
Total revenue 0.00M 0.00M 0.00M 0.00M
Total operating expenses 62.73M 22.79M 7.42M 11.36M
Cost of revenue 0.04M 0.02M 0.10M 0.11M
Total other income expense net 5.13M 2.20M 0.21M -2.20M
Net income from continuing ops -57.59M -20.59M -7.21M -13.56M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total assets 117.18M 77.51M 10.54M 16.76M
Other current assets 1.86M 0.47M 0.38M 0.39M
Total liab 10.55M 132.15M 45.34M 44.68M
Total stockholder equity 106.63M -54.64M -34.80M -27.92M
Other current liab 8.04M 2.29M 0.23M 0.24M
Capital stock 0.00M 0.00M 0.00M 0.00M
Retained earnings -115.92M -58.33M -37.74M -30.53M
Cash 47.05M 61.64M 9.73M 15.56M
Total current liabilities 10.55M 4.93M 1.38M 0.59M
Net debt -46.61M -60.86M -9.57M -15.30M
Short term debt 0.44M 0.34M 0.11M 0.10M
Short long term debt total 0.44M 0.78M 0.16M 0.26M
Other stockholder equity 222.47M 3.68M 2.94M 2.61M
Total current assets 111.89M 74.14M 10.37M 16.49M
Short term investments 62.98M 12.02M 0.25M 0.55M
Accounts payable 2.07M 2.30M 1.03M 0.26M
Accumulated other comprehensive income 0.08M - - -
Non currrent assets other 4.94M 2.63M 0.01M 0.01M
Non current assets total 5.29M 3.37M 0.17M 0.27M
Capital lease obligations 0.44M 0.78M 0.16M 0.26M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Investments -49.57M -12.00M 0.00M -1.00M
Total cashflows from investing activities -49.67M -12.00M - -1.00M
Total cash from financing activities 89.25M 81.99M 0.00M 0.23M
Net income -57.59M -20.59M -7.21M -13.56M
Change in cash -14.59M 51.91M -5.82M -11.32M
Begin period cash flow 61.64M 9.73M 15.56M 26.88M
End period cash flow 47.05M 61.64M 9.73M 15.56M
Total cash from operating activities -54.17M -18.09M -5.82M -10.54M
Issuance of capital stock 91.08M 85.33M 0.00M 0.23M
Depreciation -1.31M 0.02M 0.10M 0.11M
Other cashflows from investing activities - - - -1.00M
Sale purchase of stock 0.20M - - -
Other cashflows from financing activities 89.25M 81.66M - 1.00M
Capital expenditures 0.10M 0.11M 0.00M 0.00M
Change in working capital 0.36M 1.57M -0.08M -1.31M
Stock based compensation 3.95M 0.44M 0.31M 0.41M
Other non cash items 0.42M 0.47M 1.05M 3.81M
Free cash flow -54.27M -18.20M -5.82M -10.54M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
AARD
Aardvark Therapeutics, Inc. Common Stock		 0.14
11.97%		 1.31 - - - 1.62
NVO
Novo Nordisk A/S		 0.47
1.18%		 40.78 41.58 31.15 2.13 32.99
VRTX
Vertex Pharmaceuticals Inc		 0.34
0.06%		 547.43 30.22 24.27 10.36 6.50
REGN
Regeneron Pharmaceuticals Inc		 8.76
0.97%		 913.11 29.07 20.12 7.57 3.82
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12

Profile*

Aardvark Therapeutics, Inc. Common Stock

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

4370 La Jolla Village Drive, San Diego, CA, United States, 92122

858 225 7696

https://aardvarktherapeutics.com

28

Name Title Year Born
Dr. Tien-Li Lee M.D. CEO, Secretary & Chairman 1975
Mr. Nelson B. Sun M.B.A. CFO & COO 1977
Dr. Manasi Sinha Jaiman M.D., M.P.H. Chief Medical Officer 1981
Dr. Dvorit Samid Ph.D. Executive Vice President of Medical Affairs NA
Dr. Zhenhuan Zheng Ph.D. Chief Research Officer NA
Mr. Ron Lewis II, Ph.D. VP & Head of CMC NA
Mr. Justin T. Stege Ph.D. VP and Head of Project Management & Strategy NA
Mr. Derrick C. Li Chief Business Officer NA
Dr. Bryan Jones Ph.D. Chief Executive Officer of Ardia 1964

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.96
+38.15%
MOON
CAD 4.83
+9.64%
PDN
CAD 8.13
+7.68%
BDT
CAD 72.82
+6.65%
HG
CAD 4.28
+6.20%
CSU
CAD 3300.00
-6.42%
CURA
CAD 12.68
-4.16%
DIV
CAD 3.93
-3.44%
SOIL
CAD 7.18
-3.10%
OBE
CAD 13.31
-2.92%

Equity Sectors*

  • Basic Materials

    +3.19%

  • Communication Services

    -0.04%

  • Consumer Cyclical

    +0.27%

  • Consumer Defensive

    -0.21%

  • Energy

    +1.16%

  • Financial Services

    +0.81%

  • Healthcare

    +0.03%

  • Industrials

    +1.64%

  • Real Estate

    +0.06%

  • Technology

    +0.38%

  • Utilities

    +0.68%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…